How did Novo Nordisk get to the place it’s in now — with its inventory halved over the previous 12 months and the corporate extensively seen as trailing Eli Lilly within the weight reduction promote it as soon as led?
“I’m undecided I totally settle for the premise of the query,” Martin Lange, Novo’s head of growth, responded.
On the American Diabetes Affiliation assembly in Chicago this week, Novo executives argued the corporate is just not falling behind. Research have but to point out the total weight reduction potential of next-generation candidates corresponding to CagriSema and amycretin, they mentioned. And, they added, Novo is targeted on creating therapies that may supply shoppers a spread of choices moreover maximizing their weight reduction, relying on how briskly individuals wish to reduce weight, how prepared they’re to tolerate sure unwanted side effects, and what different illnesses they wish to deal with.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
